Telocyte is focused on developing innovative therapies to address Alzheimer's disease by targeting the underlying causes of the condition rather than merely alleviating its symptoms. The company posits that the aging of cells, particularly glial cells, leads to a cascade of pathological changes that contribute to Alzheimer's. Central to their approach is the use of telomerase therapy, which aims to reset the gene expression patterns altered by telomere shortening. This therapy is designed to enhance the cellular recycling processes that decline with age, thereby potentially reversing the accumulation of harmful proteins such as beta-amyloid and tau, which are associated with Alzheimer's pathology.

The scientific foundation of Telocyte's technology is encapsulated in a unified model of dementia that emphasizes the role of cellular aging in the progression of neurodegenerative diseases. This model suggests that as cells age, they become increasingly dysfunctional due to slowed molecular turnover and altered gene expression, leading to the accumulation of damage and the eventual loss of neuronal function. By administering a telomerase gene, Telocyte aims to relengthen telomeres in glial and neuronal cells, thereby restoring their ability to clear toxic proteins and potentially reversing the neurodegenerative processes associated with Alzheimer's disease. This novel approach represents a significant shift in the treatment paradigm for age-related neurodegeneration.

United States

We are a biotechnology company dedicated to curing Alzheimer's disease. We are planning FDA-sponsored human trials, using telomerase therapy to reset cell aging within the central nervous system. We believe that Alzheimer's disease can stopped, prevented, and cured.

Telocyte

Company Details